Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
306.8 INR | +0.15% | +13.09% | +22.83% |
04-18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
04-18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.83% | 4.39B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.87% | 22.15B | |
-17.37% | 21.02B | |
-8.19% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon : Unit Gets European Commission's Approval for Biosimilar of Cancer Drug